IP Library Granted Patent US 12,690,908
Granted Patent B2
US 12,690,908 · App. 19/546,158 · Granted Jul 28, 2026

Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry

Inventors: James Anthony Stefater, III (Boston, MA); Tomasz Pawel Stryjewski (Somerville, MA); Sameer Sabir (Arlington, MA)
Assignee: EYECOOL THERAPEUTICS, INC.
A61B18/02A61F7/10A61K9/0048A61K9/10A61K47/10A61M19/00G02C5/001A61B2018/00327A61F2007/0004A61F2007/0056A61F2007/0285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,690,908
App. No.
19/546,158
Granted
Jul 28, 2026
Kind
B2
Abstract

Disclosed herein is a method of alleviating symptoms of ocular surface discomfort, the method comprising: topically applying a cold slurry adjacent to a corneal limbus of an eye of a patient, wherein the cold slurry comprises water and a freezing point depressant, wherein the topical application of the cold slurry is configured to cause a degree of numbing of a cornea of the eye for a period of time, and wherein an ocular sensation of the eye is restored following the period of time.

Claims (27)

1 . A method of causing hypesthesia of an eye of a subject, the method comprising:

applying to at least one portion of the eye a cold slurry formulation contained within a material that is thermally conductive, such that the cold slurry formulation does not have direct contact with the at least one portion of the eye;

wherein the cold slurry formulation includes water and a freezing point depressant and the application of the cold slurry formulation causes hypesthesia of the at least one portion of the eye for a period of time of more than about two days, and an ocular sensation of the at least one portion of the eye is restored following the period of time.

2 . The method of claim 1 , wherein the at least one portion of the eye comprises a sclera.

3 . The method of claim 1 , wherein the thermally conductive material comprises at least one of a metal and a polymer.

4 . The method of claim 1 , wherein a sclera of the eye of the patient is cooled to a temperature of between about −6° C. and about 4° C. during the application of the device.

5 . The method of claim 1 , wherein application of the cold slurry formulation directs cooling only to one or more areas of potential therapeutic effect.

6 . The method of claim 1 , wherein the material that is thermally conductive substantially prevents cooling of an untargeted portion of the eye, such that undesired side effects are substantially minimized.

7 . The method of claim 6 , wherein the undesired side effects include irritation of the eye.

8 . The method of claim 1 , wherein hypesthesia includes a reduction of ocular discomfort without a complete blockage of ocular sensation.

9 . A method of causing hypesthesia of an eye of a subject, the method comprising:

applying a device to at least one portion of the eye of the subject, the device comprising a thermally conductive material comprising at least one of a metal and a polymer, the device comprising a cold slurry that comprises water and a freezing point depressant,

wherein the application of the device causes hypesthesia of the at least one portion of the eye for a period of time of more than about two days, and an ocular sensation of the at least one portion of the eye is restored following the period of time.

10 . The method of claim 9 , wherein the at least one portion of the eye comprises a sclera.

11 . The method of claim 9 , wherein the freezing point depressant is glycerol.

12 . The method of claim 9 , wherein a sclera of the eye of the patient is cooled to a temperature of between about −6° C. and about 4° C. during the application of the device.

13 . The method of claim 9 , wherein application of the cold slurry formulation directs cooling only to one or more areas of potential therapeutic effect.

14 . A method of causing hypesthesia of an eye of a subject, the method comprising:

providing a device including a thermally conductive material that contains a cold slurry formulation;

applying the device including the thermally conductive material to at least one portion of the eye;

wherein the cold slurry formulation includes water and a freezing point depressant and the application of the device causes hypesthesia of the at least one portion of the eye for a period of time of more than about two days, and an ocular sensation of the at least one portion of the eye is restored following the period of time.

15 . The method of claim 14 , wherein the at least one portion of the eye comprises a sclera.

16 . The method of claim 14 , wherein the thermally conductive material comprises at least one of a metal and a polymer.

17 . The method of claim 14 , wherein the freezing point depressant is glycerol.

18 . The method of claim 14 , wherein a sclera of the eye of the patient is cooled to a temperature of between about −6° C. and about 4° C. during the application of the device.

19 . The method of claim 14 , wherein application of the cold slurry formulation directs cooling only to one or more areas of potential therapeutic effect.

20 . The method of claim 14 , wherein hypesthesia includes a reduction of ocular discomfort without a complete blockage of ocular sensation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2026
From: STEFATER, JAMES ANTHONY, III; STRYJEWSKI, TOMASZ PAWEL; SABIR, SAMEER
To: BRIXTON BIOSCIENCES, INC.
Reel/Frame 074427/0355 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2026
From: BRIXTON BIOSCIENCES, INC.
To: EYECOOL THERAPEUTICS, INC.
Reel/Frame 074427/0449 →
Continuity (7)
Continuation 18948163 · Nov 14, 2024
Continuation 18907345 · Oct 4, 2024
Continuation 18299444 · Apr 12, 2023
Continuation 17839674 · Jun 14, 2022
Continuation 17439749 · Mar 26, 2021
Provisional Application 63000922 · Mar 27, 2020
Related Publication 20260183039A1 · Jul 2, 2026
References Cited (171)
US 2101628A · Padelford · 1937 [cited by applicant]
US 2313282A · Tunke · 1943 [cited by applicant]
US 2796903A · Gazelle · 1957 [cited by applicant]
US 3762419A · Walters · 1973 [cited by applicant]
US 4068918A · Holcombe, Jr. · 1978 [cited by applicant]
US 4243041A · Paul · 1981 [cited by applicant]
US 5190033A · Johnson · 1993 [cited by applicant]
US 5368590A · Itoh · 1994 [cited by applicant]
US 5514094A · Anello et al. · 1996 [cited by applicant]
US 5953097A · Stark · 1999 [cited by applicant]
US 6099521A · Shadduck · 2000 [cited by applicant]
US 6241711B1 · Weissberg et al. · 2001 [cited by applicant]
US 6409746B1 · Igaki et al. · 2002 [cited by applicant]
US 6824556B1 · Lachance · 2004 [cited by applicant]
US 7930772B2 · Fontanez · 2011 [cited by applicant]
US 8257256B1 · Krolman · 2012 [cited by applicant]
US 8262715B2 · Wong, Jr. et al. · 2012 [cited by applicant]
US 8439960B2 · Burnett et al. · 2013 [cited by applicant]
US 8992516B2 · Muller · 2015 [cited by applicant]
US 9144513B2 · Paulson · 2015 [cited by applicant]
US D787694S · Baltazar · 2017 [cited by applicant]
US 9956355B2 · Besirli et al. · 2018 [cited by applicant]
US 10201471B2 · Yang · 2019 [cited by applicant]
US 10238814B2 · Besirli et al. · 2019 [cited by applicant]
US 10322248B2 · Besirli et al. · 2019 [cited by applicant]
US 10369056B2 · Paulson · 2019 [cited by applicant]
US 10420674B2 · Johnson · 2019 [cited by applicant]
US 11241330B1 · Sabir et al. · 2022 [cited by applicant]
US 11399882B2 · Stefater, III et al. · 2022 [cited by applicant]
US 11471401B2 · Garibyan et al. · 2022 [cited by applicant]
US D968627S · Kim · 2022 [cited by applicant]
US 11564830B2 · Garibyan et al. · 2023 [cited by applicant]
US 11653969B2 · Stefater, III et al. · 2023 [cited by applicant]
US 20020049389A1 · Abreu · 2002 [cited by applicant]
US 20040249427A1 · Nabilsi · 2004 [cited by applicant]
US 20050120734A1 · Yon · 2005 [cited by applicant]
US 20070282282A1 · Wong, Jr. · 2007 [cited by examiner]
US 20080148769A1 · Higgins · 2008 [cited by applicant]
US 20090275936A1 · Muller · 2009 [cited by applicant]
US 20110307041A1 · Floyd · 2011 [cited by applicant]
US 20130158637A1 · Sheikh · 2013 [cited by applicant]
US 20140025144A1 · Ragan · 2014 [cited by applicant]
US 20140081361A1 · Dhayan · 2014 [cited by applicant]
US 20150165231A1 · Scheja et al. · 2015 [cited by applicant]
US 20160000600A1 · Lee · 2016 [cited by applicant]
US 20160279350A1 · Besirli et al. · 2016 [cited by applicant]
US 20170231816A1 · Ryan · 2017 [cited by applicant]
US 20170274011A1 · Garibyan et al. · 2017 [cited by applicant]
US 20170304558A1 · Besirli et al. · 2017 [cited by applicant]
US 20170368298A1 · Bojanova · 2017 [cited by applicant]
US 20180289533A1 · Johnson et al. · 2018 [cited by applicant]
US 20190015602A1 · Besirli et al. · 2019 [cited by applicant]
US 20190053939A1 · Garibyan et al. · 2019 [cited by applicant]
US 20190125579A1 · Habib · 2019 [cited by applicant]
US 20190167916A1 · Besirli et al. · 2019 [cited by applicant]
US 20190328753A1 · Yee et al. · 2019 [cited by applicant]
US 20200054483A1 · Kim · 2020 [cited by applicant]
US 20200100934A1 · Ariano et al. · 2020 [cited by applicant]
US 20200163797A1 · Besirli et al. · 2020 [cited by applicant]
US 20200206023A1 · Pathak et al. · 2020 [cited by applicant]
US 20200215144A1 · Yang · 2020 [cited by applicant]
US 20210007882A1 · Kim · 2021 [cited by applicant]
US 20210145500A1 · Barken · 2021 [cited by examiner]
US 20220218514A1 · Azar et al. · 2022 [cited by applicant]
US 20240207183A1 · Sabir et al. · 2024 [cited by applicant]
CN 106214325A · 2016 [cited by applicant]
CN 106344397A · 2017 [cited by applicant]
CN 106691685A · 2017 [cited by applicant]
CN 107280854A · 2017 [cited by applicant]
CN 107736962A · 2018 [cited by applicant]
CN 107773350A · 2018 [cited by applicant]
CN 108272549A · 2018 [cited by applicant]
CN 108524098A · 2018 [cited by applicant]
CN 108743030A · 2018 [cited by applicant]
CN 108814802A · 2018 [cited by applicant]
CN 108815584A · 2018 [cited by applicant]
CN 109077909A · 2018 [cited by applicant]
CN 109077947A · 2018 [cited by applicant]
CN 110025463A · 2019 [cited by applicant]
CN 110215335A · 2019 [cited by applicant]
CN 110279517A · 2019 [cited by applicant]
CN 110393623A · 2019 [cited by applicant]
CN 110393624A · 2019 [cited by applicant]
CN 110433272A · 2019 [cited by applicant]
CN 110755193A · 2020 [cited by applicant]
CN 110809457A · 2020 [cited by applicant]
CN 110882103A · 2020 [cited by applicant]
CN 111096846A · 2020 [cited by applicant]
CN 111297557A · 2020 [cited by applicant]
CN 217366288U · 2022 [cited by applicant]
CN 115957067A · 2023 [cited by applicant]
CN 116439904A · 2023 [cited by applicant]
DE 29712559U1 · 1997 [cited by applicant]
DE 202013102909U1 · 2013 [cited by applicant]
DE 202015102909U1 · 2015 [cited by applicant]
FR 2909545A1 · 2008 [cited by applicant]
GB 2537833A · 2016 [cited by applicant]
JP H0661224U · 1994 [cited by applicant]
JP 2007511293A · 2007 [cited by applicant]
JP 2017526684A · 2017 [cited by applicant]
JP 2019506248A · 2019 [cited by applicant]
KR 1020060084878A · 2006 [cited by applicant]
KR 200422938Y1 · 2006 [cited by applicant]
KR 2020100002818U · 2010 [cited by applicant]
KR 2020100009316U · 2010 [cited by applicant]
KR 20100107157A · 2010 [cited by applicant]
KR 101107942B1 · 2012 [cited by applicant]
KR 20130007077A · 2013 [cited by applicant]
KR 101486160B1 · 2015 [cited by applicant]
KR 101544610B1 · 2015 [cited by applicant]
KR 101827457B1 · 2018 [cited by applicant]
KR 101851179B1 · 2018 [cited by applicant]
MX PA06005434A · 2007 [cited by applicant]
WO WO2001039704A1 · 2001 [cited by applicant]
WO WO2005049071A2 · 2005 [cited by applicant]
WO WO2007102362A1 · 2007 [cited by applicant]
WO WO2010039117A1 · 2010 [cited by applicant]
WO WO2015011455A1 · 2015 [cited by applicant]
WO WO2015149536A1 · 2015 [cited by applicant]
WO WO2015149537A1 · 2015 [cited by applicant]
WO WO2016010355A1 · 2016 [cited by applicant]
WO WO2016033384A1 · 2016 [cited by applicant]
WO WO2017147367A1 · 2017 [cited by applicant]
WO WO2018160797A1 · 2018 [cited by applicant]
WO WO2018225913A1 · 2018 [cited by applicant]
WO WO2020117030A1 · 2020 [cited by applicant]
WO WO2021016457A1 · 2021 [cited by applicant]
WO WO2022261494A1 · 2022 [cited by applicant]
WO WO2023154902A1 · 2023 [cited by applicant]
WO WO2023215407A2 · 2023 [cited by applicant]
WO WO2024163973A1 · 2024 [cited by applicant]
“Anesthesia for Eye Surgery: On Improving Retinal Anesthesia Technology,” Bold Business article, Mar. 2, 2018 (https://www.Boldbusiness.Com/Health/Anesthesia-For-Eye-Surgery-Technology) (8 pages). [cited by applicant]
Alcaine—proparacaine hydrocholoride solution/drops, Alcon Laboratories, Inc., 2020 (6 pages). [cited by applicant]
Andreoli, C. M., et al. Open globe injuries: Emergent evaluation and initial management, In: UpToDate, Post TW (Ed), Up To Date, Waltham, MA (Literature review current through Aug. 2021; topic last updated Feb. 2020) (3… [cited by applicant]
Belmonte, C., et al., “Sensory Innervation of the Eye”, Chapter 16, Adler's Physiology of the Eye (Eleventh Edition), pp. 363-384, 2011, Elsevier Inc. (22 pages). [cited by applicant]
Benson, M. T., et al., “Cyclocryotherapy: a review of cases over a 10-year period,” British Journal of Ophthalmology, 1990, 74, pp. 103-105 (3 pages). [cited by applicant]
Besirli, Cagri G., et al., Randomized Safety and Feasiblity Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections, Ophthalmol Retina, Apr. 15, 2020; S2468-6530(20)30142-1, doi: 10.1016/j.oret.2020.04.001 (… [cited by applicant]
Bras, Alvaro, et al., “Safety Alert: Risks associated with Ophthalmic Anesthetics,” reviewed by Dr. S. Brodovsky, MD, FRCSC, WRHA Pharmacy Program, Sep. 2016 (4 pages). [cited by applicant]
Chao, Daniel L., et al., A Novel Rapid Cooling Device for Intravitreal Injection Anesthesia: Results of the Prospective COOL-2 Study, Investigative Ophthalmology & Visual Sicence, vol. 61, 4196, ARVO Annual Meeting Abst… [cited by applicant]
Chee, C. K. L., et al., “Cyclocryotherapy for chronic glaucoma after vitreoretinal surgery,” Eye 8, pp. 414-418, 1994 (5 pages). [cited by applicant]
Heiting, G., Cornea of the eye. All About Vision, 2017 (retrieved from https://www.allaboutvision.com/resources/cornea.htm) (7 pages). [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, mailed Jul. 8, 2021, for International Application No. PCT/US2021/024514 (8 pages). [cited by applicant]
Kim, Byoung Seon, et al., “Long term Results from Cyclocryotherapy Applied to the 3O'clock and 9O'clock Positons in Blind Refractory Glaucoma Patients,” Korean J Ophthalmol 2015; 29(1): 47-52, doi 10.3341/kjo.2015.29.1.… [cited by applicant]
Lee, B. S., et al., “Managing dry eye disease and facilitating realistic patient expectations: A review and appraisal of current therapies,” Clinical Ophthalmology 2020, 14: 119-126, published online Jan. 14, 2020, doi:… [cited by applicant]
Levitt, A E., et al., “Chronic dry eye symptoms after LASIK: parallels and lessons to be learned from other persistent post-operative pain disorders,” Molecular Pain (2015), 11 :21, doi 10.1186/s12990-015-0020-7 (12 pag… [cited by applicant]
Lindsell, Lucas B., et al., “Use of Topical Ice for Local Anesthesia for Intravitreal Injections,” JAMA Ophthalmology, Aug. 2014, vol. 132, No. 8, pp. 1010-1011 (2 pages). [cited by applicant]
Mcmonnies, C. W., “The potential role of neuropathic mechanisms in dry eye syndromes,” Journal of Optometry (2017), 10, 5-13, doi: http://dx.doi.org/10.1016/j.optom.2016.06.002 (9 pages). [cited by applicant]
Mcmonnies, C. W., The potential role of neuropathic mechanisms in dry eye syndromes, Journal of Optomertry, 2016, ttp://dx.doi.org/10.1016/j.optom.2016.06.002 (9 pages). [cited by applicant]
NDA 208135: Tetracaine hydrochloride ophthalmic solution, FDA, Apr. 30, 2015 (26 pages). [cited by applicant]
Pathak, A. K., et al., Pain reduction after photoablation. EyeWiki by the American Academy of Ophthalmology, 2019 (2 pages). [cited by applicant]
Recens Medical, Inc., “Cooling Anesthesia for Intravitreal Injection (COOL-1),” ClinicalTrials.gov Identifier: NCT03732287, First Posted Nov. 6, 2018 (7 pages). [cited by applicant]
Shah, Anjali, “Cryoanesthesia for Intravitreal Injections,” NCT02872012, Protocol Version 4.0, Oct. 11, 2017 (15 pages). [cited by applicant]
Shetty, R., et al., “Pain management after photorefractive keratectomy,” Journal of Cataract & Refractive Surgery, vol. 45, Issue 7, pp. 972-976, Jul. 2019, doi: 10.1016/j .jcrs2019.01.032 (5 pages). [cited by applicant]
Sowka, Joseph et al., “Just an Eyedrop? Think Again,” Review of Optometry, vol. 143:03, Issue: Mar. 15, 2006, published May 3, 2006 (3 pages). [cited by applicant]
Spierer, Oriel, et al. “Corneal mechanical thresholds negatively associate with dry eye and ocular pain symptoms,” Investigative Ophthalmolgy & Visual Science, vol. 57, 617-625, Feb. 2016 , doi: 10.1167/iovs.15-18133 (9… [cited by applicant]
Sridhar, M. S., “Anatomy of cornea and ocular surface.,” Indian Journal of Ophthalmology, 66(2), 190-194, Feb. 2018, doi: 10.4103/ijo.IJO _ 646 _ 17 (13 pages). [cited by applicant]
Video: Dr. Najeeb Lectures, Ciliary Ganglion—Gross Anatomy, https://www.youtube.com/watch?v=6kH6Fg7ES6E), posted Jun. 6, 2014 (7 pages). [cited by applicant]
Video: Soton Brain Hub, The Ciliary Ganglion, https://www.youtube.com/watch?v=kQiP-zuNEHA, posted Aug. 8, 2015 (3 pages). [cited by applicant]
Zarei-Ghanavati, S., et al., “Efficacy of corneal cooling on postoperative pain management after photorefractive keratectomy: A contralateral eye randomized clinical trial,” Journal of Current Ophthalmology, vol. 29, Is… [cited by applicant]
Olson, J. and Stravino, V., “A Review of Cryotherapy,” Physical Therapy, vol. 52, No. 8, pp. S40-S53 (Aug. 1972). [cited by applicant]
Cataldi, J.K., et al., “Cryotherapy Effects, Part 2: Time to Numbness Onset and Numbness Duration,” International Journal of Athletic Therapy & Training, vol. 18, No. 5, pp. 26-28 (Sep. 2013). [cited by applicant]
Attia, A.A.M. and Hassan, A.M., “Effect of cryotherapy on pain management at the puncture site of arteriovenous fistula among children undergoing hemodialysis,” International Journal of Nursing Sciences, vol. 4, pp. 46-… [cited by applicant]
Fraunfelder, F., “Liquid Nitrogen Cryotherapy for Surface Eye Disease (An AOS Thesis),” Transactions of the American Ophthalmological Society, vol. 106, pp. 301-324 (46 total pages), PMCID: PMC2646430, PMID: 19277243 (2… [cited by applicant]
Morkin, M.I. and Hamrah, P., “Efficacy of Self-Retained Cryopreserved Amniotic Membrane for Treatment of Neuropathic Corneal Pain,” The Ocular Surface, vol. 16, Issue 1, pp. 132-138 (Author Manuscript—25 total pages), r… [cited by applicant]
Reitberger, H.H., et al., “Argon cold plasma—a novel tool to treat therapy-resistant corneal infections,” American Journal of Ophthalmology, doi: 10.1016/j.ajo.2018.03.025, Author Manuscript—27 total pages (Accepted Mar… [cited by applicant]
Shetty, R., et al., “Cold bandage contact lens use reduces post-photorefractive keratectomy or corneal collagen-crosslinking pain perception in patients,” Indian Journal of Ophthalmology, vol. 71, No. 5, pp. 1885-1861 (… [cited by applicant]
International Search Report and Written Opinion issued Jun. 21, 2024 by U.S. Patent and Trademark Office as International Searching Authority for International Bureau of WIPO in International Patent Application No. PCT/… [cited by applicant]
Office Action issued by China National Intellectual Property Administration on May 29, 2025 in Chinese Patent Application No. 202180024320.9 with partial English translation (15 total pages). [cited by applicant]
Office Action issued Sep. 5, 2025 by China National Intellectual Property Administration in Chinese Patent Application No. 202180024320.9 with partial English translation (17 total pages). [cited by applicant]
Final Office Action issued Sep. 17, 2025 by U.S. Patent and Trademark Office in U.S. Appl. No. 19/048,089 (9 total pages). [cited by applicant]
Final Office Action issued Jul. 29, 2025 by U.S. Patent and Trademark Office in U.S. Appl. No. 18/948,163 (11 total pages). [cited by applicant]